|
KMID : 0370220240680010071
|
|
Yakhak Hoeji
2024 Volume.68 No. 1 p.71 ~ p.78
|
|
|
Immunogenicity of Recombinant Influenza Vaccine Compared with Inactivated Influenza Vaccine on the Prevention of Influenza Virus: A Systematic Review and Meta-analysis
|
|
Cha Youn-Sun
An Eun-Ji
Kwon Sun-Hong
Lee Eui-Kyung
|
|
|
Abstract
|
|
|
|
To compare surrogate markers of immunogenicity between recombinant and inactivated influenza vaccines, thisstudy conducted a systematic review and meta-analysis for each strain. Three databases of Medline (Pubmed), Embase andCochrane Central were searched to identify all published literature up to July 2023. Out of a total of 1,658 initiallyidentified articles, 14 randomized controlled trials were selected based on inclusion and exclusion criteria. The program Rversion 4.3.1 was used to estimate the mean difference of geometric mean titer (GMT) and the pooled risk ratio (RR) ofseroconversion and seroprotection with 95% confidence intervals. The meta-analysis results found higher GMT effect sizesfor recombinant influenza vaccines compared to inactivated vaccines for A/H3N2 (MD=124.87, 95% CI 52.63-197.11) andB/Yamagata (MD=19.89, 95% CI 7.61-32.17) strains. In terms of seroconversion rates, recombinant influenza vaccinesexhibited higher seroconversion for A/H3N2 (RR=1.33, 95% CI 1.26-1.40) and B/Yamagata (RR=1.75, 95% CI 1.06-2.89)strains. Slightly higher seroprotection rates were observed for A/H3N2 (RR=1.04, 95% CI 1.02-1.07) and B/Yamagata(RR=1.07, 95% CI 1.01-1.13) strains with recombinant vaccines. The findings from this study contribute valuable evidencefor regulatory decisions when introducing recombinant vaccines in South Korea.
|
|
|
KEYWORD
|
|
|
Influenza vaccine, Immunogenicity, Systematic review, Meta-analysis
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|